BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 15291906)

  • 1. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
    Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
    Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
    Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
    Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
    Kopp MV; Stenglein S; Kamin W; Friedrichs F; von Berg A; Zielen S; Hamelmann E; Wahn U; Kuehr J
    Pediatr Allergy Immunol; 2007 Sep; 18(6):523-7. PubMed ID: 17680911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
    Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
    J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
    Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
    Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
    Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
    J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
    Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
    Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific IgE serum concentration is associated with symptom severity in children with seasonal allergic rhinitis.
    Rolinck-Werninghaus C; Keil T; Kopp M; Zielen S; Schauer U; von Berg A; Wahn U; Hamelmann E;
    Allergy; 2008 Oct; 63(10):1339-44. PubMed ID: 18782113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of nasal immunohistology in patients with seasonal rhinoconjunctivitis treated with topical steroids or specific allergen immunotherapy.
    Rak S; Heinrich C; Scheynius A
    Allergy; 2005 May; 60(5):643-9. PubMed ID: 15813810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood.
    Eng PA; Borer-Reinhold M; Heijnen IA; Gnehm HP
    Allergy; 2006 Feb; 61(2):198-201. PubMed ID: 16409196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
    Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
    J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.